OptimizeRx Cuts Revenue Outlook: Will Pressures Ease Ahead?

OptimizeRx Corporation OPRX trimmed its 2026 revenue outlook, reflecting ongoing near-term pressures. Revenues are now expected to be between $95 million and $100 million, compared with the previous range of $109-$114 million.

Zacks Investment Research • May 15, 2026

OptimizeRx Q1 Earnings Call Highlights

OptimizeRx NASDAQ: OPRX reported first-quarter fiscal 2026 results that topped consensus expectations, while management lowered its full-year revenue outlook, citing continued caution among life sciences customers and shorter contract commitments tied in part to most-favored-nation pricing dynamics and other macroeconomic pressures.

MarketBeat • May 13, 2026

OptimizeRx Corporation (OPRX) Q1 2026 Earnings Call Transcript

OptimizeRx Corporation (OPRX) Q1 2026 Earnings Call Transcript

Seeking Alpha • May 13, 2026

OptimizeRx Reports First Quarter 2026 Financial Results and Updates Fiscal Year 2026 Guidance

– Q1 revenue totals $19.8 million– Q1 net loss and adjusted EBITDA came in at $(0.5) million and $3.3 million, respectively– 2026 revenue guidance updated to $95-$100 million; adjusted EBITDA guidance unchanged at $21-$25 million– Paid off an incremental $2.7 million in principal from term loan during Q1– Completed debt refinancing, subsequent to end of Q1, with a $35 million traditional banking facility, resulting in expected $1.5 million in annual interest expense savings– Launched operating efficiency initiatives, subsequent to end of Q1, with expected annualized savings of $3 million, including $1 million in 2026 WALTHAM, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today announced results for the three months ended March 31, 2026.

GlobeNewsWire • May 12, 2026

OptimizeRx Corp. (OPRX) Surpasses Q1 Earnings and Revenue Estimates

OptimizeRx Corp. (OPRX) came out with quarterly earnings of $0.14 per share, beating the Zacks Consensus Estimate of $0.01 per share. This compares to earnings of $0.08 per share a year ago.

Zacks Investment Research • May 12, 2026

OptimizeRx Expands EHR Advertising Reach With New DSP Integration

OPRX launched a programmatic EHR ad connection for DSPs, expanding point-of-care targeting and access to authenticated inventory.

Zacks Investment Research • May 12, 2026

OptimizeRx Launches Programmatic Access to Authenticated EHR Advertising at Scale

Expands life sciences marketers' reach at the validated point of care, enabling DSPs to directly integrate with OptimizeRx's trusted EHR network for the first time Expands life sciences marketers' reach at the validated point of care, enabling DSPs to directly integrate with OptimizeRx's trusted EHR network for the first time

GlobeNewsWire • May 11, 2026

Should You Add OPRX Stock to Your Portfolio Pre-Q1 Earnings?

OptimizeRx nears Q1 earnings amid declining revenue forecasts, softer trends and a cautious outlook, raising questions on near-term upside.

Zacks Investment Research • May 7, 2026

Earnings Preview: OptimizeRx Corp. (OPRX) Q1 Earnings Expected to Decline

OptimizeRx (OPRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research • May 5, 2026

Are Investors Undervaluing OptimizeRx (OPRX) Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Investment Research • May 4, 2026